| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Lilly Research Laboratories (H.Z., W.W., M.B.B., S.S., J.G., A.M.E.), D-22419 Hamburg, Germany; and Bartholin Instituttet (K.B.), Rigshospitalet, DK-2100 Copenhagen, Denmark
Address all correspondence and requests reprints to: Dr. Alexander M. Efanov, Lilly Research Laboratories, Essener Bogen 7, D-22419 Hamburg, Germany. E-mail: efanov_alexander{at}lilly.com.
Liver X receptors (LXR
and LXRß) regulate glucose and lipid metabolism. Pancreatic ß-cells and INS-1E insulinoma cells express only the LXRß isoform. Activation of LXRß with the synthetic agonist T0901317 increased glucose-induced insulin secretion and insulin content, whereas deletion of the receptor in LXRß knockout mice severely blunted insulin secretion. Analysis of gene expression in LXR agonist-treated INS-1E cells and islets from LXRß-deficient mice revealed that LXRß positively regulated expression of ATP-binding cassette transporter A1 (ABCA1), sterol regulatory element-binding protein 1 (SREBP-1), insulin, PDX-1, glucokinase, and glucose transporter 2 (Glut2). Down-regulation of SREBP-1 expression with the specific small interfering RNA blocked basal and LXRß-induced expression of pancreatic duodenal homeobox 1 (PDX-1), insulin, and Glut2 genes. SREBP-1 small interfering RNA also prevented an increase in insulin secretion and insulin content induced by T0901317. Moreover, 5-(tetradecyloxy)-2-furoic acid, an inhibitor of the SREBP-1 target gene acetyl-coenzyme A carboxylase, blocked T0901317-induced stimulation of insulin secretion. In conclusion, activation of LXRß in pancreatic ß-cells increases insulin secretion and insulin mRNA expression via SREBP-1-regulated pathway. These data support the role of LXRß, SREBP-1, and cataplerosis/anaplerosis pathways in the control of insulin secretion in pancreatic ß-cells.
This article has been cited by other articles:
![]() |
C. D. Green, D. B. Jump, and L. K. Olson Elevated Insulin Secretion from Liver X Receptor-Activated Pancreatic {beta}-Cells Involves Increased de Novo Lipid Synthesis and Triacylglyceride Turnover Endocrinology, June 1, 2009; 150(6): 2637 - 2645. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Diraison, M. A. Ravier, S. K. Richards, R. M. Smith, H. Shimano, and G. A. Rutter SREBP1 is required for the induction by glucose of pancreatic {beta}-cell genes involved in glucose sensing J. Lipid Res., April 1, 2008; 49(4): 814 - 822. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Choe, A H. Choi, J.-W. Lee, K. H. Kim, J.-J. Chung, J. Park, K.-M. Lee, K.-G. Park, I.-K. Lee, and J. B. Kim Chronic Activation of Liver X Receptor Induces {beta}-Cell Apoptosis Through Hyperactivation of Lipogenesis: Liver X Receptor-Mediated Lipotoxicity in Pancreatic {beta}-Cells Diabetes, June 1, 2007; 56(6): 1534 - 1543. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Chen, P. B. Jeppesen, I. Nordentoft, and K. Hermansen Stevioside improves pancreatic beta-cell function during glucotoxicity via regulation of acetyl-CoA carboxylase Am J Physiol Endocrinol Metab, June 1, 2007; 292(6): E1906 - E1916. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Wente, M. B. Brenner, H. Zitzer, J. Gromada, and A. M. Efanov Activation of Liver X Receptors and Retinoid X Receptors Induces Growth Arrest and Apoptosis in Insulin-Secreting Cells Endocrinology, April 1, 2007; 148(4): 1843 - 1849. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |